Premium
Complete resolution of minocycline pigmentation following a single treatment with non‐ablative 1550‐nm fractional resurfacing in combination with the 755‐nm Q‐switched alexandrite laser
Author(s) -
Vangipuram Ramya K.,
DeLozier Whitney L.,
Geddes Elizabeth,
Friedman Paul M.
Publication year - 2016
Publication title -
lasers in surgery and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.888
H-Index - 112
eISSN - 1096-9101
pISSN - 0196-8092
DOI - 10.1002/lsm.22463
Subject(s) - minocycline , medicine , ablative case , dermatology , laser , skin type , hyperpigmentation , acne , surgery , optics , radiation therapy , antibiotics , chemistry , biochemistry , physics
Pigmentation secondary to minocycline ingestion is an uncommon adverse event affecting 3.7–14.8% of treated individuals for which few effective therapies are available. Three patterns of minocycline pigmentation have a characteristic clinical and histological appearance. The pigment composition in each variety is different and occurs at varying skin depths. Accordingly, a tailored approach according to the type of minocycline pigmentation is crucial for treatment success. The purpose of this intervention was to evaluate the efficacy of non‐ablative fractional photothermolysis in combination with the Q‐switched alexandrite laser for the treatment of type I minocycline pigmentation on the face. A patient with type I minocycline pigmentation was treated with non‐ablative 1550‐nm fractional photothermolysis followed immediately by 755‐nm Q‐switched alexandrite laser and then observed clinically to determine the outcome of this modality. The patient was seen in clinic 1 month later following her single treatment session and 100% clearance of all blue facial pigment was observed. Non‐ablative fractional photothermolysis in combination with the 755‐nm Q‐switched alexandrite laser should be considered for treatment of type I minocycline pigmentation. Lasers Surg. Med. 48:234–237, 2016. © 2015 Wiley Periodicals, Inc.